Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants

Phase 1 Completed 58 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Merck KGaA, Darmstadt, Germany · collab

RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), and safety and tolerability of evobrutinib after oral administration of immediate release (IR) and modified release (MR) formulations in healthy participants.

Timeline

Start: 2022-02-02
Primary completion: 2023-02-14
Completion: 2023-02-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Evobrutinib	Small molecule	—	Oral

Indications

No indication recorded.